Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse

Muscle Nerve. 2015 Oct;52(4):498-502. doi: 10.1002/mus.24624. Epub 2015 Jul 24.

Abstract

Introduction: Electrodiagnostic studies (EDX) are not performed routinely before treatment suspension in CIDP, and no data exist regarding their value in predicting clinical relapse.

Methods: Serial EDX (baseline and after IGIV-C therapy) were analyzed from subjects in the ICE clinical trial who responded to IGIV-C treatment and were subsequently re-randomized to placebo in an extension phase. Comparisons were made between subjects who relapsed and those who did not.

Results: A total of 55% (6/11) of the Relapse group had an increase in total number of demyelinating findings (DF) versus 8% (1/13) in the No Relapse group (P = 0.023). In the Relapse group, 100% had ≥ 1 new DF and 73% (8/11) had ≥ 4 new DF versus 60% (8/13) and 8% (1/13), respectively, in the No Relapse group.

Conclusions: An increased total number of DF or the occurrence of ≥ 4 new DF may indicate a higher risk of clinical relapse after treatment cessation in IGIV-C-responsive patients.

Keywords: CIDP; IVIG; NCS; demyelinating criteria; relapse.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Action Potentials / drug effects
  • Adult
  • Aged
  • Electrodiagnosis
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Neural Conduction / drug effects*
  • Neural Conduction / physiology
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / physiopathology
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / therapy*
  • Reaction Time
  • Recurrence
  • Treatment Outcome*

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors